February 23, 2024European Journal of Preventive Cardiology

Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study

View Full Paper

Ask AI

Bookmark

Combining a moderate-intensity statin with ezetimibe lowers the risk of primary cardiovascular outcomes compared to high-intensity statin monotherapy.
Hazard ratio reached 0.84 for composite cardiovascular disease events and all-cause death, alongside lower risks of stroke and myocardial infarction.
Propensity-matched nationwide cohort study evaluated health registry data, tracking Korean individuals without pre-existing cardiovascular disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Nationwide cohort study finds moderate-intensity statin plus ezetimibe lowers cardiovascular events better than high-intensity statin monotherapy, highlighting dual therapy benefits.

Cite This Study

Jun et al. (2024) studied this question.

synapsesocial.com/papers/68e77c94b6db6435876f106f https://doi.org/10.1093/eurjpc/zwae081

View Full Paper

Ask AI

Bookmark

Implication

Nationwide cohort study finds moderate-intensity statin plus ezetimibe lowers cardiovascular events better than high-intensity statin monotherapy, highlighting dual therapy benefits.

Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study

Key Points

Discussion

Implication

Cite This Study

Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider